Endo begins Mersana's foray into antibody-drug conjugates with $270 million deal
This article was originally published in Scrip
Mersana Therapeutics announced a collaboration agreement with Endo Pharmaceuticals worth up to $270 million plus royalties, its first deal in antibody-drug conjugates (ADCs).
You may also be interested in...
During a month when only two biotechnology companies have gone public, private drug developers continue to raise hundreds of millions of dollars in venture capital.
Development of gosuranemab in tauopathies will end after a Phase II progressive supranuclear palsy trial failure, but a Phase II Alzheimer’s study of the drug licensed from BMS is ongoing.
Public Company Edition: The last biopharma initial public offering in the US was on 11 November, but follow-on and other offerings are generating hundreds of millions of dollars. Among RNA drug developers, Ionis issued more than $500m in new debt, while Arrowhead raised $266.8m.